We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Protein Expression of Programmed Death 1 Ligand 1 and HER2 in Gastric Carcinoma.
- Authors
Oki, Eiji; Okano, Shinji; Saeki, Hiroshi; Umemoto, Yuichiro; Teraishi, Koji; Nakaji, Yu; ando, Koji; Zaitsu, Yoko; Yamashita, Nami; Sugiyama, Masahiko; Nakashima, Yuichiro; Ohgaki, Kippei; Oda, Yoshinao; Maehara, Yoshihiko
- Abstract
Objectives: Programmed death 1 (PD-1) is an immunoinhibitory receptor and has been identified as a new target for immunotherapy in cancer. Here we report the expression of PD-1 ligand 1 (PD-L1) in surgically resected gastric cancer. Materials and Methods: We examined formalin-fixed tumor samples from 144 gastric cancer patients with a primary diagnosis of gastric carcinoma. Immunohistochemistry was used to detect PD-L1. Human epidermal growth factor receptor 2 (HER2) expression and phosphatase and tensin homolog (PTEN) loss of heterozygosity were investigated in these patients. RNA interference was used to downregulate HER2 expression, and PD-L1 protein expression was assessed by flow cytometry using the gastric cancer cell line MKN45. Results: Overexpression of PD-L1 was significantly correlated with tumor invasion ( p = 0.011) and associated with poor survival. The number of PD-L1-positive cases in-creased according to the HER2 score in clinical samples. siRNA-mediated downregulation of HER2 significantly decreased PD-L1 protein expression in MKN45 cells. Conclusions: PD-L1 expression was associated with poor survival of gastric cancer, and HER2 signaling affects the expression of PD-L1 in gastric cancer. In gastric cancer, PTEN and HER2 are potential candidate biomarkers for developing human antibodies that block PD-L1.
- Subjects
EPIDERMAL growth factor; FLOW cytometry; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; LIGANDS (Biochemistry); ONCOGENES; STOMACH tumors
- Publication
Oncology, 2017, Vol 93, Issue 6, p387
- ISSN
0030-2414
- Publication type
Article
- DOI
10.1159/000479231